Review of Eight Pharmacoeconomic Studies of the Value of Biologic DMARDs Adalimumab, Etanercept, and Infliximab) in the Management of Rheumatoid Arthritis
Journal of Managed Care Pharmacy
doi 10.18553/jmcp.2006.12.7.555
Full Text
Open PDFAbstract
Available in full text
Date
September 1, 2006
Authors
Publisher
Academy of Managed Care Pharmacy